目的 研究丙戊酸钠联合帕利哌酮治疗精神分裂症的临床疗效。方法 选择2014年4月—2016年1月到北京市昌平区中西医结合医院诊治的精神分裂症患者104例，随机分为对照组和治疗组，每组各52例。对照组口服帕利哌酮缓释片，起始剂量为6 mg/d，1周内根据病情将剂量调整为6～9 mg/d。治疗组在对照组治疗基础上口服丙戊酸钠缓释片，起始剂量为0.5 g/d，最大剂量为1.5～2.0 g/d，可根据病情酌情加减。两组患者均持续治疗12周。观察两组的临床疗效，同时比较两组治疗前后阴性和阳性症状量表（PANSS）评分和个人和社会功能量表（PSP）评分的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为80.77%、94.23%，两组比较差异有统计学意义（P<0.05）治疗后6、12周，两组阳性症状评分、阴性症状评分、精神病理评分、PANSS总分显著下降，PSP评分显著升高，同组治疗前后差异有统计学意义（P<0.05），且治疗组这些评分的改善程度优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 丙戊酸钠联合帕利哌酮治疗精神分裂症疗效显著，有效缓解临床症状，改善社会功能，安全性好，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of sodiumvalproate combined with paliperidone in treatment of schizophrenia. Methods Patients (104 cases) with schizophrenia in Changping Hospital of Integrated Chinese and Western Medicine from April 2014 and January 2016 were randomly divided into control and treatment groups. Each group had 52 cases. The patients in the control group were po administered with Paliperidone Extended-Release Tablets, and the starting dosage was 0.5 g/d, than the dosage was adjusted to 1.5-2.0 mg/d according to condition of patients within 1 week. The patients in the treatment group were po administered with SodiumValproate Sustained Release Tablets on the basis of the control group, and the starting dosage was 1 mg/d, and the largest dosage was 4-6 mg/d, and the dosage was discretionary added and subtracted according to the illness condition. The patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and the changes of PANSS scores and PSP scores in two groups before and after treatment were compared. Results After treatment, the total efficacies in the control and treatment groups were 80.77% and 94.23%, respectively, and there were differences between two groups (P<0.05). After treatment of 6 and 12 weeks, positive symptom score, negative symptom scores, psychiatric pathology scores, and PANSS total scores were significantly decreased, and PSP was significantly increased, the difference was statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Sodiumvalproate combined with paliperidone has clinical curative effect in treatment of schizophrenia, and can relieve clinical symptoms effectively, also can improve social function with high safety, which has a certain clinical application value.